Specialty Pharmacy

If approved, alectinib would be the only anaplastic lymphoma kinase inhibitor to show reductions in risk of recurrence or death for those with early-stage lung cancer.

Additional research is needed to further evaluate whether adequate emotional support is linked to improvements in health-related quality of life in adults diagnosed with other cancer.

Manufacturers must find the right balance in drug pricing, so that medications are appealing to both public and private insurers while still remaining profitable throughout their lifecycle.

This year's survey features questions focused on compensation, fulfillment, and burnout.

Spatially resolved technology based on next-generation sequencing has the potential to benefit clinical practice and improve the prognosis for cancer patients.

Despite the limited data, prior research indicates there are no serious cannabis-related adverse effects in pediatric patients.

The seamless integration of artificial intelligence and machine learning has the potential to accelerate research and enhance efficiency in a new era of personalized medicine.

Advanced technology can automate many pharmacovigilance tasks to build workflow efficiencies, reduce manual intervention, and free up team members for more strategic activities.

Perhaps the most significant development in the pharmaceutical industry in decades, crops of biosimilars are being approved and are ready for distribution. What lies next, in terms of legislation and the impact on pharmacists, remains to be seen.

The research was aided by the Decipher Genomics Resource for Intelligent Discovery, which helped derive the gene signatures used during the analysis.

The drug can now be tested for safety, tolerability, and efficacy in a phase 1 study.

The recent discovery could aid further research on the cause of Huntington’s disease and other inherited conditions.

During the phase 1b/2 trials, CAR T-cell therapy demonstrated significant and clinical survival benefits.

Generative artificial intelligence is a type of self-learning software that can increase the time pharmacists can allocate to patients, improve medication adherence, and allow patients to access health data on a whim.

The treatment is the first of its kind to be FDA-approved to treat CHAPLE disease.

Pharmacists will have the opportunity to use their knowledge of biosimilars to reinforce their benefits, safety, and efficacy.

Expert weighs in on the growth of specialty drug spending, particularly with drugs in immunology, neurology, and weight loss.

Many studies with a stated goal of advancing child health care in administratively-defined minors have no clinical value and may even harm young patients.

Pharmacists can improve patient access to both healthful foods and necessary medicines as a continuum of care in underserved communities.

Educator and pharmacy advocate encourages pharmacists to work together to improve the scope of the profession and patient access to services.

Findings may have therapeutic implications because of the potential to target neurotransmitters to treat or prevent melanoma.

Although additional studies are needed, findings indicate that mtDNAfb may be a useful biomarker for future risk of non-Hodgkin lymphoma.

Improved prescription information could help consumers make better health care decisions and result in cost savings.

Early safety studies of NK-cell infusion have demonstrated the potential of NK-cell infusion, showing it may be the next revolution in cancer treatment.

Specialty pharmacists play an important role in dispensing PCSK9 inhibitors and serve as a valuable source of assistance and education for patients.

In terms of science and technology, the health care community has everything needed to clinically implement pharmacogenomics testing.

Risks of genitourinary and gastrointestinal toxicity were reduced significantly, but longer follow-up is necessary to examine potential future issues.

A panel of experts discuss the state of biosimilars today and the importance of standardizing knowledge of the field.

Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.

Managing cost savings can soften the blow of direct and indirect remuneration fee reform that will impact pharmacists during the first half of 2024.